A Recombinant Antibody to Siglec-8 Shows Selective ADCC Activity Against Mast Cells from Systemic Mastocytosis Patients

@article{Falahati2015ARA,
  title={A Recombinant Antibody to Siglec-8 Shows Selective ADCC Activity Against Mast Cells from Systemic Mastocytosis Patients},
  author={Rustom Falahati and J. Bright and A. Dorenbaum and C. Bebbington and N. Toma{\vs}evi{\'c} and D. Lidke and T. George and J. Gotlib},
  journal={Blood},
  year={2015},
  volume={126},
  pages={4092-4092}
}
  • Rustom Falahati, J. Bright, +5 authors J. Gotlib
  • Published 2015
  • Medicine
  • Blood
  • Background: Systemic mastocytosis (SM) is a rare myeloproliferative neoplasm characterized by the accumulation of neoplastic mast cells (MC) in one or more extracutaneous organs. In all forms of SM, anti-mediator drugs are used to control symptoms of MC degranulation. In advanced forms of SM, organ damage is common and patients (pts) exhibit reduced life expectancy. In these individuals, cytoreductive agents such as cladribine and interferon-alpha have been used off-label, and inhibitors of KIT… CONTINUE READING
    2 Citations
    Functions and therapeutic targets of Siglec-mediated infections, inflammations and cancers.
    • 4
    Endotype-driven precision medicine in chronic rhinosinusitis
    • 5